- Oops!Something went wrong.Please try again later.
DGAP-News: ABIVAX / Key word(s): Half Year Report
Abivax announces the release of its 2021 half-year financial report
PARIS, France, September 30, 2021 - 6:00 pm (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2021 half-year financial report. This document is available in electronic version on the website of the company (www.abivax.com - "Investors") and on the website of the French financial markets authority, AMF (www.amf-france.org).
About Abivax (www.abivax.com)
30.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.